Compare · BLFS vs INMD
BLFS vs INMD
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and InMode Ltd. (INMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and INMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- BLFS is the larger of the two at $1.03B, about 1.1x INMD ($912.4M).
- Over the past year, BLFS is down 12.7% and INMD is up 1.0% - INMD leads by 13.8 points.
- BLFS has been more active in the news (5 items in the past 4 weeks vs 1 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- InMode Ltd.
- Price
- $21.36-1.79%
- $14.40+0.14%
- Market cap
- $1.03B
- $912.4M
- 1M return
- +7.39%
- +4.80%
- 1Y return
- -12.75%
- +1.02%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 1
- Recent ratings
- 8
- 20
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Latest BLFS
- BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
- SEC Form 4 filed by Mathew Aby J.
- SEC Form 4 filed by Berard Todd
- SEC Form 4 filed by Wichterman Troy
- SEC Form 4 filed by Foster Karen A.
- Amendment: SEC Form SCHEDULE 13G/A filed by BioLife Solutions Inc.
- SEC Form 4 filed by De Greef Roderick
- SEC Form 4 filed by Berard Todd
- SEC Form 4 filed by Werner Sean
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.